Bringing Together Regulators, Pharma, and Scientific Leaders to Shape the Future of Antiviral Strategies
AVITHRAPID, the cutting-edge European initiative dedicated to accelerating antiviral research and pandemic preparedness, is proud to announce the launch of AVITHRAPID SEMINARS—a dynamic series of expert-driven discussions uniting regulatory authorities, pharmaceutical industry leaders, European projects, and key stakeholders.
A Platform for Innovation and Collaboration
The AVITHRAPID SEMINARS aim to foster strategic dialogue on antiviral innovation, therapeutic development, and public health security. These sessions will serve as a bridge
between science, policy, and industry, ensuring that the latest advancements in antiviral
research translate into impactful policies and real-world applications.
The first closed-door seminar is scheduled for Monday, March 3, 2025, featuring a high-level
discussion with HERA (DG SANTE), focusing on pandemic preparedness and antiviral
strategies. Two public sessions will follow in Summer and Autumn 2025, welcoming industry experts, policymakers, and researchers to exchange insights and shape the future of antiviral
preparedness.
Join the Conversation
AVITHRAPID invites pharmaceutical companies, research consortia, public health
institutions, and regulatory stakeholders to take part in upcoming seminars.
To express interest or request participation, contact us at engage@chelonia.swiss
Stay tuned for more details on the next sessions by following our website and social channels.
About AVITHRAPID
AVITHRAPID is a European research initiative dedicated to accelerating antiviral drug discovery, leveraging advanced technologies and interdisciplinary collaboration to strengthen
global health security against emerging viral threats.
Partners:
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V., First Health
Pharmaceuticals B.V., Instituto de Medicina Molecular Joao Lobo Antunes (iMM), Institut
national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE), Università
degli Studi della Tuscia (UNITUS), Università degli Studi di Siena (UNISI), Elettra
Sincrotrone Trieste SCOA, Latvian Institute of Organic Synthesis (LIOS), Université de Tours
(UT), University of Naples Federico II (UNINA), Swiss Tropical and Public Health Institute
(Swiss TPH), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (INMI),
Università degli Studi di Cagliari, Università degli Studi di Roma “Tor Vergata”, Dompé
Farmaceutici SpA, Euresist Network GEIE, IT4Innovations and Chelonia SA